Back to Search Start Over

Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry.

Authors :
González García, Andrés
Fabregate, Martin
Manzano, Luis
Guillén del Castillo, Alfredo
Rubio Rivas, Manuel
Argibay, Ana
Marín Ballvé, Adela
Rodríguez Pintó, Ignasi
Pla Salas, Xavier
Marí-Alfonso, Begoña
Callejas Moraga, Eduardo
Colunga Argüelles, Dolores
Sáez Comet, Luis
González-Echávarri, Cristina
Ortego-Centeno, Norberto
Vargas Hitos, José Antonio
Todolí Parra, José Antonio
Trapiella Martínez, Luis
Herranz Marín, María Teresa
Freire, Mayka
Source :
Seminars in Arthritis & Rheumatism; Aug2022, Vol. 55, pN.PAG-N.PAG, 1p
Publication Year :
2022

Abstract

●Left ventricular diastolic dysfunction is common in systemic sclerosis and the cumulative survival was worse. ● Left ventricular diastolic dysfunction is associated with older age, telangiectasia and treatment with calcium channel blockers. Objectives: Left ventricular diastolic dysfunction (LVDD) remains poorly studied in Systemic Sclerosis (SSc). To determine the prevalence and to define factors associated with LVDD and survival in a large cohort of patients with SSc. Methods: An observational study was conducted with data from the multicentre Spanish Scleroderma Registry (RESCLE) to identify factors associated with LVDD and estimate survival. Results: Out of 1517 patients, 319 (21.0%) had LVDD. The subset of sine scleroderma SSc was associated to LVDD (14.7% vs. 10.6%, p =0.048), whilst diffuse cutaneous SSc was more prevalent in non-LVDD (16.0 % vs. 21.2%, p =0.041). Multivariable analysis identified that LVDD was associated with older age at diagnosis of SSc (OR 1.05; 95% CI 1.04 to 1.06), longer time from diagnosis (OR 1.04; 95% CI 1.03 to 1.06), presence of telangiectasia (OR 1.42; 95% CI 1.08 to 1.88), treatment with calcium channel blockers (CCB) (OR 1.51; 95% CI 1.16 to 1.96), and inversely related to angiotensin-converting-enzyme inhibitors (ACEi) use (OR 0.59; 95% CI 0.44 to 0.80). SSc patients with LVDD had increased mortality (23.8 vs. 17.4%, p =0.010) and shortened survival from the first SSc symptom (p =0.040), even though it was not found to be an independent risk factor for death. Conclusions: LVDD is relatively common in SSc patients, and it is associated with worst prognosis, older age, longer time from diagnosis of SSc, presence of telangiectasia and vasodilator treatment. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00490172
Volume :
55
Database :
Supplemental Index
Journal :
Seminars in Arthritis & Rheumatism
Publication Type :
Academic Journal
Accession number :
157762642
Full Text :
https://doi.org/10.1016/j.semarthrit.2022.152033